Nordic Issuing

Ongoing case

DanCann Pharma A/S

Back to all cases

DanCann Pharma A/S

16 May - 31 May 2023Warrant exercise TO 2

DanCann Pharma is a Danish biopharmaceutical company powered by cannabinoids, licensed for production and distribution of products based on cannabinoids.

Cannabinoids is the active components from the plant cannabis. The Company conducts its business through work with both cannabis and cannabinoids as handling of the cannabis plant is part of the process in producing cannabinoids, the component used for therapeutic and medical purposes. DanCann Pharma is an early-stage company with the intention to establish itself on the European medicinal cannabis market. The Company is overall focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics in a broad range of disease areas, dedicated to the commercialization of innovative prescription products targeting the European market.

Read more on the company's website

The offer in summary

Subscription period: 16 May - 31 May 2023

Price per share: DKK 0.36

Trading with warrants: 16 May - 29 May 2023

The offer: 21 927 810 shares

Payment day: 31 May 2023

Market place: Spotlight Stock Market

Financial advisor: Corpura Fondkommission AB


  Subscription form TO 2


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.